Published in Biomaterials on March 27, 2006
Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol (2013) 1.16
Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharm (2009) 1.11
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J Vis Exp (2013) 1.04
Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine (2014) 1.02
Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks. Springerplus (2013) 0.81
Sustained release of methotrexate through liquid-crystalline folate nanoparticles. J Mater Sci Mater Med (2014) 0.80
Nanomicellar carriers for targeted delivery of anticancer agents. Ther Deliv (2014) 0.80
Application of in situ polymerization for design and development of oral drug delivery systems. AAPS PharmSciTech (2010) 0.79
Nanomedicine strategies for treatment of secondary spinal cord injury. Int J Nanomedicine (2015) 0.79
Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide). Curr Opin Solid State Mater Sci (2012) 0.78
Oral delivery of capsaicin using MPEG-PCL nanoparticles. Acta Pharmacol Sin (2014) 0.77
Design of vitamin E d-α-Tocopheryl Polyethylene Glycol 1000 Succinate-Emulsified Poly (D,L-Lactide-co-Glycolide) Nanoparticles: Influence of Duration of Ultrasonication Energy. J Young Pharm (2011) 0.77
Nanostructured Cubosomes in a Thermoresponsive Depot System: An Alternative Approach for the Controlled Delivery of Docetaxel. AAPS PharmSciTech (2015) 0.76
Key parameters affecting the initial leaky effect of hemoglobin-loaded nanoparticles as blood substitutes. J Mater Sci Mater Med (2008) 0.75
Archaeosome: as new drug carrier for delivery of Paclitaxel to breast cancer. Indian J Clin Biochem (2013) 0.75
Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer. Indian J Clin Biochem (2013) 0.75
XAV939: from a small inhibitor to a potent drug bioconjugate when delivered by gold nanoparticles. Bioconjug Chem (2014) 0.75
In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea. Indian J Clin Biochem (2013) 0.75
Biodegradable mixed MPEG-SS-2SA/TPGS micelles for triggered intracellular release of paclitaxel and reversing multidrug resistance. Int J Nanomedicine (2016) 0.75
Effects of poly(L-lactide-ε-caprolactone) and magnesium hydroxide additives on physico-mechanical properties and degradation of poly(L-lactic acid). Biomater Res (2016) 0.75
Antiplasmodial Activity and Toxicological Assessment of Curcumin PLGA-Encapsulated Nanoparticles. Front Pharmacol (2017) 0.75
The use of nanoparticulates to treat breast cancer. Nanomedicine (Lond) (2017) 0.75
Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 2.77
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 1.55
Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials (2007) 1.49
Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials (2012) 1.39
Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials (2006) 1.32
Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials (2007) 1.29
Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials (2003) 1.27
Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials (2011) 1.25
PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res (2003) 1.20
Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res (2013) 1.20
Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials (2009) 1.18
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials (2008) 1.14
Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials (2013) 1.12
Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev (2012) 1.11
Paclitaxel drug delivery systems. Expert Opin Drug Deliv (2013) 1.09
Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials (2010) 1.08
Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. Biomaterials (2008) 1.07
In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules (2006) 1.04
In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials (2005) 1.02
Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A (2006) 1.01
Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials (2012) 1.01
Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release (2013) 1.00
In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res (2008) 1.00
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials (2008) 1.00
Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials (2012) 0.96
Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials (2010) 0.94
Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J Colloid Interface Sci (2005) 0.93
Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm (2011) 0.93
Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials (2007) 0.93
Self-assembled nanoparticles of poly(lactide)--Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm (2006) 0.92
Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. J Colloid Interface Sci (2004) 0.91
Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond) (2010) 0.91
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res A (2010) 0.91
Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci (2010) 0.90
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials (2010) 0.90
Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm (2010) 0.90
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials (2011) 0.89
Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm (2007) 0.89
Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J Control Release (2002) 0.89
In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials (2007) 0.88
Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int J Pharm (2011) 0.88
Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine (Lond) (2012) 0.87
Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials (2011) 0.87
Folic acid-functionalized two-photon absorbing nanoparticles for targeted MCF-7 cancer cell imaging. Chem Commun (Camb) (2011) 0.86
Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm (2010) 0.86
Pharmaceutical stability aspects of nanomedicines. Nanomedicine (Lond) (2009) 0.85
d-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified poly(l-lactide) (PLLA) films for localized delivery of paclitaxel. Int J Pharm (2007) 0.83
Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials (2013) 0.83
Formulation, characterization, and in vitro evaluation of quantum dots loaded in poly(lactide)-vitamin E TPGS nanoparticles for cellular and molecular imaging. Biotechnol Bioeng (2008) 0.82
Effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within the lipid monolayer at the air-water interface. J Colloid Interface Sci (2006) 0.82
Block copolymer micelles for nanomedicine. Nanomedicine (Lond) (2012) 0.82
Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond) (2011) 0.82
Polyethylenimine coating to produce serum-resistant baculoviral vectors for in vivo gene delivery. Biomaterials (2009) 0.82
Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system. J Control Release (2005) 0.81
Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials (2013) 0.81
Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success. Expert Opin Drug Deliv (2012) 0.81
Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des (2010) 0.80
Herceptin functionalized polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide nanoparticles for tumor cell sorting and detection. Biomaterials (2011) 0.80
siRNA-based nanomedicine. Nanomedicine (Lond) (2013) 0.80
Nanomedicine for multimodality treatment of cancer. Nanomedicine (Lond) (2012) 0.80
Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond) (2010) 0.80
Autophagy inhibition strategy for advanced nanomedicine. Nanomedicine (Lond) (2014) 0.79
Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine (Lond) (2014) 0.79
Prodrug micelle-based nanomedicine for cancer treatment. Nanomedicine (Lond) (2013) 0.79
Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) (2009) 0.79
Nanoimmunotherapy: application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine (Lond) (2012) 0.79
Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. Int J Pharm (2012) 0.79
Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv (2013) 0.79
Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials (2011) 0.79
Facile synthesis of water-stable magnetite nanoparticles for clinical MRI and magnetic hyperthermia applications. Nanomedicine (Lond) (2010) 0.79
Nanomedicine for oral chemotherapy. Nanomedicine (Lond) (2011) 0.78
Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine (Lond) (2012) 0.78
Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond) (2012) 0.78
Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine (Lond) (2010) 0.78
Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine (Lond) (2014) 0.78
Nanothermotherapy by high performance magnetic nanoparticles. Nanomedicine (Lond) (2010) 0.78
Conjugated polymer loaded nanospheres with surface functionalization for simultaneous discrimination of different live cancer cells under single wavelength excitation. Anal Chem (2011) 0.78
Polymeric nanoparticulates for cancer immunotherapy. Nanomedicine (Lond) (2013) 0.77
CD20 Antibody-Conjugated Immunoliposomes for Targeted Chemotherapy of Melanoma Cancer Initiating Cells. J Biomed Nanotechnol (2015) 0.77
Star-shaped block polymers as a molecular biomaterial for nanomedicine development. Nanomedicine (Lond) (2014) 0.77
Copolymer technology for advanced nanomedicine. Nanomedicine (Lond) (2011) 0.77
Nanohydrogels as a prospective member of the nanomedicine family. Nanomedicine (Lond) (2013) 0.77
Nanomedicine for diabetes treatment. Nanomedicine (Lond) (2011) 0.76
DSC and EPR investigations on effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within lipid bilayer membrane. Int J Pharm (2007) 0.76
Targeted nanomedicine for detection and treatment of circulating tumor cells. Nanomedicine (Lond) (2011) 0.76
Nanomedicine for the treatment of triple-negative breast cancer. Nanomedicine (Lond) (2014) 0.76
Multimodal imaging for cancer detection. Nanomedicine (Lond) (2010) 0.75
Herceptin®-conjugated nanocarriers for targeted imaging and treatment of HER2-positive cancer. Nanomedicine (Lond) (2011) 0.75
Synthesis of hydrophilic superparamagnetic magnetite nanoparticles via thermal decomposition of Fe(acac), in 80 vol% TREG + 20 vol% TREM. J Nanosci Nanotechnol (2011) 0.75
The synergistic effect of herceptin and docetaxel in polylactide-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles. J Control Release (2011) 0.75
Nanotechnology for multimodal imaging. Nanomedicine (Lond) (2011) 0.75
Thermochemotherapy mediated by novel solar-planet structured magnetic nanocomposites for glioma treatment. J Nanosci Nanotechnol (2012) 0.75
Investigation of molecular interactions between paclitaxel and DPPC by Langmuir film balance and differential scanning calorimetry. J Pharm Sci (2004) 0.75
Nanomedicine for treatment of cancer stem cells. Nanomedicine (Lond) (2014) 0.75